An analysis of the COMPASS trial in patients with GFR ≥60 or <60 mL/min showed consistent treatment benefit of the combination of rivaroxaban 2.5 mg bd plus aspirin, vs aspirin alone.
The FDA has approved alirocumab to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established CVD, based on ODYSSEY OUTCOMES data.
No interaction was observed between diabetes status, guided DAPT de-escalation therapy vs. control therapy and outcomes in ACS patients after PCI.
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.
A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.
ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.
ACC 2019 The AUGUSTUS trial showed less bleeding and fewer hospitalizations without differences in ischemic events with apixaban and no aspirin, as compared with regimens with VKA, aspirin or both.
In a secondary analysis of the VISTA-16 trial, hsCRP levels measured at the time of ACS and increases of hsCRP in the 16 weeks after, were correlated with MACE, all-cause and CV death.
RETRACTION 7 Out of 13 studies included in a meta-analysis of RCTs on atorvastatin loading prior to PCI for ACS should have been excluded based on the study’s selection criteria. A corrected analysis substantively alters the results.
A retrospective analysis of RCTs suggests that when ischemic and bleeding risks are concordant, bleeding risk should inform decision-making on DAPT duration more so than ischemic risk.
Noise from road traffic, railway and aircraft were associated with MI mortality in a cohort of adults, independently of air pollution, in a model that assessed individual exposure at the address and floor level.
Self-reported consumption of ≥2 artificially sweetened beverages per day was associated with higher risk of CV events, and all-cause mortality in postmenopausal women, as shown in an observational study.